Bharat Biotech partners with Alopexx to develop antimicrobial vaccine | Company News

Bharat Biotech CEO Krishna Ella said the aim is to develop solutions to reduce antimicrobial resistance through vaccination. | Photo: Shutterstock

Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for the development and commercialization of the latter’s broad-spectrum antimicrobial vaccine in India and other low-income countries.

As part of the collaboration, the companies will jointly develop and commercialize the vaccine, AV0328, in India and other approved territories, Bharat Biotech said in a statement.

Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it added.

“Our goal is to develop solutions to reduce antimicrobial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable and high-quality vaccines to combat infectious diseases globally,” said Bharat Biotech CEO Krishna Ella.

Alopexx CEO Daniel Vlock said this collaboration brings the company one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low- and middle-income countries.

He further said that Bharat Biotech’s support “is not only crucial for the advancement of AV0328, but will also significantly strengthen our overall clinical programs.”

“The broad and revolutionary potential of our platforms in treating a wide range of bacterial, fungal and parasitic infections represents a transformative approach to combatting infectious diseases on a global scale,” Vlock added.

A first-in-human Phase I trial has been completed, demonstrating that AV0328 is well tolerated and no serious adverse events have been observed, the statement said.

(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First published: September 11, 2024 | 14:12 IS

Source link

Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.

Leave a Comment